{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-26-000048","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-08-13T20:05:58+00:00","discovered_at":"2026-08-13T20:08:00.285010+00:00","generated_at":"2026-08-13T20:08:06.695722+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Serina reports Q2 net loss of $8.9M, advances SER-252 trial ahead of schedule","bullets":["Net loss attributable to common shareholders was $8.9M, or $(0.55) per share, vs $6.6M loss ($(0.66)) in Q2 2025.","Operating expenses rose to $6.8M from $5.7M; R&D $3.8M, G&A $3.0M; cash $23.0M at June 30, 2026.","Completed enrollment/dosing of all 8 patients in Cohort 1 of SER-252 Phase 1b registrational study in July 2026, ahead of Q3 2026 guidance.","Top-line data from single-ascending-dose arm targeted for H1 2027; partnered with Gannet BioChem for process development and manufacturing.","Appointed Farrell Simon, Pharm.D., to Board of Directors and Audit/Compensation Committees in July 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-26-000048","json":"https://secwatch.observer/filing/0001708599-26-000048.json","markdown":"https://secwatch.observer/filing/0001708599-26-000048.md","text":"https://secwatch.observer/filing/0001708599-26-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000048/0001708599-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000048/ser-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:08:06.695722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}